Region:Global
Product Code:GH02206R
In-vivo CRO refers to the preclinical testing performed for preclinical testing of disease pathology and drug discovery. It provides information regarding the collection and investigation of data for the development of new drugs for the treatment of various indications. The global oncology based in-vivo cro market was valued at USD 1,077 million in 2021 to USD 1,707 million by 2028, progressing at a CAGR of 6.8% from 2022 to 2028, according to Gen Consulting Company.
The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global oncology based in-vivo cro market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the oncology based in-vivo cro industry.
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the indication, and region. The global market for oncology based in-vivo cro can be segmented by indication: blood cancer, solid tumors (syngeneic model, patient-derived xenograft (PDX), xenograft), others. Oncology based in-vivo cro market is further segmented by region: Asia Pacific, Europe, North America, Rest of the World (RoW).
By indication:
- blood cancer
- solid tumors (syngeneic model, patient-derived xenograft (PDX), xenograft)
- others
By region:
- Asia Pacific
- Europe
- North America
- Rest of the World (RoW)
The report explores the recent developments and profiles of key vendors in the Global Oncology Based In-Vivo CRO Market, including Charles River Laboratories International, Inc., Crown Bioscience, Inc., Eurofins Scientific SE, Evotec SE, ICON Plc, Laboratory Corporation of America Holdings (Labcorp), Taconic Biosciences, Inc., The Jackson Laboratory, WuXi AppTec Co., Ltd., XenTech SAS, among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
Historical & Forecast Period
This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.
Scope of the Report
- To analyze and forecast the market size of the global oncology based in-vivo cro market.
- To classify and forecast the global oncology based in-vivo cro market based on indication, region.
- To identify drivers and challenges for the global oncology based in-vivo cro market.
- To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global oncology based in-vivo cro market.
- To identify and analyze the profile of leading players operating in the global oncology based in-vivo cro market.
Why Choose This Report
- Gain a reliable outlook of the global oncology based in-vivo cro market forecasts from 2022 to 2028 across scenarios.
- Identify growth segments for investment.
- Stay ahead of competitors through company profiles and market data.
- The market estimate for ease of analysis across scenarios in Excel format.
- Strategy consulting and research support for three months.
- Print authentication provided for the single-user license.
TABLE OF CONTENTS
FIGURES AND TABLES
PART 1. INTRODUCTION
- Report description
- Objectives of the study
- Market segment
- Years considered for the report
- Currency
- Key target audience
PART 2. METHODOLOGY
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
- Introduction
- Drivers
- Restraints
- Impact of COVID-19 pandemic
PART 5. MARKET BREAKDOWN BY INDICATION
- Blood cancer
- Solid tumors (syngeneic model, patient-derived xenograft (PDX), xenograft)
- Others
PART 6. MARKET BREAKDOWN BY REGION
- Asia Pacific
- Europe
- North America
- Rest of the World (RoW)
PART 7. KEY COMPANIES
- Charles River Laboratories International, Inc.
- Crown Bioscience, Inc.
- Eurofins Scientific SE
- Evotec SE
- ICON Plc
- Laboratory Corporation of America Holdings (Labcorp)
- Taconic Biosciences, Inc.
- The Jackson Laboratory
- WuXi AppTec Co., Ltd.
- XenTech SAS
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.